BDSX
BIODESIX INC
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$21.49
+2.09%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$21.88
From 52W high−29.77%
Volume147918.00
Market cap$226.74M
P/E (TTM)—
P/S (TTM)2.2x
Div yield—
Key dataNov 4, 2026
Open
$21.88
From 52W high
−29.77%
Volume
147918.00
Market cap
$226.74M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−18.8x
P/E (TTM)
—
RSI (14)
35.6
MomentumView details →
1D Return
+2.09%
YTD Return
+202.79%
SummaryUpdated Jun 1, 2026
Biodesix, Inc. (NASDAQ:BDSX) is a data-driven diagnostic solutions company founded in 2005 and headquartered in Boulder, Colorado. Originally incorporated as Elston Technologies, Inc., the company went public in October 2020. Biodesix specializes in blood-based diagnostic tests for lung disease, particularly focusing on lung cancer risk assessment and treatment guidance. The company has evolved from a research-focused organization into a commercial-stage diagnostics company with a growing sales force and expanding test portfolio.
Similar companies
Latest newsMore news →
Biodesix announced that it will release its third-quarter 2026 financial results after market close on November 5, 2026, and hold a conference call and webcast at 4:30 p.m. Eastern Time that day.14d agoBIODESIX INC announced a partnership with Vanderbilt University and Vanderbilt University Medical Center to accelerate development of a radiomics-based test for lung nodule risk assessment.17d agoBiodesix announced two complementary approaches to molecular residual disease (MRD) monitoring, a tumor-informed program and a tumor-naïve program, drawing on its bioinformatics and diagnostics test development expertise.42d ago